iMediSync

iMediSync (www.imedisync.com) has developed an AI-driven early detection and therapeutic platform for optimal brain health, iSyncBrain®. iMediSync launched its first solution to detect amnestic Mild Cognitive Impairment or aMCI (early stage of Alzheimer&s;s Disease) based on its proprietary EEG database in Korea in August 2020(iSyncBrain MCI Classifier - KFDA Cleared). The Company conducted a clinical trial with multicenter hospitals resulting in 90%+ accuracy for its solution. The vision of iMediSync, for its iSyncBrain® MCI Classifier, is to develop early detecting biomarkers for challenging neurological disorders such as Parkinson&s;s disease, TBI, PTSD, ADHD, and Depression.